A Phase II Single Center Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor (GM CSF and Ifosfamide Carboplatin Etoposide) For Patients With Relapsed Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Ifosfamide (Primary) ; Irinotecan (Primary) ; Naxitamab (Primary) ; Temozolomide (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 05 Jun 2024 New trial record